Although metastatic breast cancer (mBC) remains incurable, significant gains in our understanding of its molecular basis have resulted in new, targeted therapies. These advances, combined with expert care by interdisciplinary health care teams, are making prolonged life, delayed progression, and preserved quality of life a possibility for many patients.
eNewsletter with interactive benchmarking
To improve awareness of the latest guidelines and therapies for mBC, encourage a team approach to care, and improve patient adherence to therapies for improved outcomes.
After completing this activity, participants should be better able to:
- Discuss clinical trial evidence for available and emerging therapies for hormone receptor–positive (HR+) mBC, including the place and timing of these therapies in clinical practice
- Devise evidence-based management plans for patients with HR+ mBC
- Address challenges to patient quality of life by incorporating effective treatment with management of side effects and promotion of adherence
Oncology nurse practitioners, physician assistants, and nurses
In support of improving patient care, this activity has been planned and implemented by Continuing Education Alliance and the American Academy of PAs (AAPA). Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing contact hours: 1.00, which includes 0.50 hours of pharmacology credit
CNE course advisor: Cynthia L. Teeple, APRN, MSN, ONP
This program has been reviewed and is approved for a maximum of 1.00 AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of June 9, 2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or Lilly.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Tolaney: research support: Exelixis, Genentech, Lilly, Novartis, Pfizer.
The Planning Committee for this activity included Ruth Cohen and Warren Beckman of Continuing Education Alliance; Cynthia L. Teeple, APRN, MSN, ONP, of Purchase, New York; and Jessica Garner, MMS, PA-C, of the University of the Pacific. The members of the Planning Committee have no significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the eNewsletter in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: June 9, 2017
Expiration date: June 9, 2018
© 2018 Practicing Clinicians Exchange. All Rights Reserved. LPCE92117